Department of Radiology, Leeds Teaching Hospitals, Leeds, UK.
Postgrad Med J. 2010 Mar;86(1013):174-82. doi: 10.1136/pgmj.2009.079087.
Integrated positron emission tomography/CT (PET/CT) with 2-[(18)F]fluoro-2-deoxy-d-glucose (FDG) is a hybrid imaging modality which has recently become established in the staging, restaging and therapy response assessment of oncology patients. FDG PET/CT has several recognised applications in colorectal cancer (CRC) imaging including preoperative evaluation of apparently limited metastatic disease, detection of disease recurrence, clarification of equivocal lesions at initial staging, investigation of unexplained rising tumour markers, and incidental detection of occult primary colonic tumours. With a constantly advancing body of evidence and increasing availability, applications of PET/CT in CRC are likely to emerge in therapy response assessment, radiotherapy planning, use of novel tracers and 'one-stop' imaging techniques such as iodinated contrast-enhanced PET/CT. With the use of illustrative clinical examples, this article reviews the utility of FDG PET/CT in the management of CRC, discussing its role and limitations in the multimodality imaging of these patients.
正电子发射断层扫描/计算机断层扫描（PET/CT）与 2-[(18)F]氟-2-脱氧-d-葡萄糖（FDG）的结合是一种混合成像方式，最近已在肿瘤患者的分期、再分期和治疗反应评估中确立。FDG PET/CT 在结直肠癌（CRC）成像中有几个公认的应用，包括术前评估明显局限性转移疾病、检测疾病复发、澄清初始分期时的可疑病变、调查不明原因的肿瘤标志物升高，以及偶然发现隐匿性原发性结肠肿瘤。随着越来越多的证据不断涌现，PET/CT 在 CRC 中的应用可能会出现在治疗反应评估、放射治疗计划、新型示踪剂的使用以及碘造影剂增强 PET/CT 等“一站式”成像技术中。本文通过举例说明，回顾了 FDG PET/CT 在 CRC 管理中的应用，讨论了其在这些患者的多模态成像中的作用和局限性。
